Skip to main content
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. — Investor Relations & Filings

Ticker · PLX ISIN · US74365A3095 LEI · 549300SDVB3GP4XDFM60 US Manufacturing
Open in API
Filings indexed 950 across all filing types
Latest filing 2021-08-16 Interim / Quarterly Rep…
Country US United States of America
Listing US PLX

About Protalix BioTherapeutics, Inc.

https://protalix.com/

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins. The company's unique selling point is its proprietary ProCellEx® platform, a plant cell-based protein expression system used to manufacture complex proteins. This technology supports the development of treatments for rare and orphan diseases. Protalix has successfully brought enzyme replacement therapies to market and maintains a pipeline of product candidates targeting conditions with high unmet medical needs. The company's capabilities cover the entire process from protein candidate selection and genetic engineering of plant cells through preclinical and clinical development to commercial-scale production and marketing.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2021
2021-08-16 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates by a company. The text specifically mentions that the company issued a press release announcing its financial results for the second quarter ended June 30, 2021, and provided a financial and business update. The document includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The length of the document is 3786 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, if a document is short and announces or furnishes a report (like a press release of earnings), it should be classified as an Earnings Release (ER). The Form 8-K is used here to announce the earnings release and financial update, which fits the Earnings Release category rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K). Therefore, the appropriate classification is ER with high confidence.
2021-08-16 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into material definitive agreements related to the exchange of convertible notes, including detailed terms of the financing transaction. It also references the filing of exhibits such as the Exchange Agreement and a press release. This type of filing is an update on financing activities and capital structure changes, not a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2021-08-13 English
SCHEDULE 13G/A
Major Shareholding Notification
2021-07-30 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated July 7, 2021, by Protalix BioTherapeutics, Inc. The content focuses on the submission of matters to a vote of security holders at the 2021 Annual Meeting of Stockholders. It details the voting results for the election of directors, advisory approval of executive compensation, and ratification of the appointment of the independent auditor. This matches the description of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document is about the official results from shareholder votes at a general meeting, not the meeting materials or the full annual report. The length is 4403 characters, which is consistent with a voting results announcement rather than a full report. Therefore, the correct classification is DVA with high confidence.
2021-07-07 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details an At The Market Offering Agreement for common stock, including terms of the offering, use of proceeds, risk factors, and plan of distribution. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not a financial report, earnings release, or management discussion. It is clearly related to financing activities and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, not just an announcement or a brief notice, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2021-07-02 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.